Activation of ADAM17 by IL-15 Limits Human NK Cell Proliferation.
ADAM17 Protein
/ antagonists & inhibitors
Adoptive Transfer
Animals
Cell Division
Enzyme Activation
Female
Heterografts
Humans
Interleukin-15
/ metabolism
Killer Cells, Natural
/ cytology
L-Selectin
/ metabolism
Mice
Mice, Inbred NOD
Mice, SCID
Receptors, Cell Surface
/ metabolism
Recombinant Proteins
/ pharmacology
ADAM17 (a disintegrin and metalloprotease 17)
CD62L
IL-15
natural killer cell
proliferation
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
18
05
2021
accepted:
07
07
2021
entrez:
9
8
2021
pubmed:
10
8
2021
medline:
21
12
2021
Statut:
epublish
Résumé
Natural killer (NK) cells are innate cytotoxic lymphocytes that can recognize assorted determinants on tumor cells and rapidly kill these cells. Due to their anti-tumor effector functions and potential for allogeneic use, various NK cell platforms are being examined for adoptive cell therapies. However, their limited
Identifiants
pubmed: 34367174
doi: 10.3389/fimmu.2021.711621
pmc: PMC8339566
doi:
Substances chimiques
IL15 protein, human
0
Interleukin-15
0
Receptors, Cell Surface
0
Recombinant Proteins
0
SELL protein, human
0
L-Selectin
126880-86-2
ADAM17 Protein
EC 3.4.24.86
ADAM17 protein, human
EC 3.4.24.86
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
711621Subventions
Organisme : NCI NIH HHS
ID : P01 CA065493
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA111412
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA203348
Pays : United States
Informations de copyright
Copyright © 2021 Mishra, Dixon, Pore, Felices, Miller and Walcheck.
Déclaration de conflit d'intérêts
Author NP was employed by company AstraZeneca. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Immune Netw. 2020 Mar 09;20(2):e14
pubmed: 32395366
J Exp Med. 2005 Dec 19;202(12):1679-89
pubmed: 16352740
J Exp Med. 2009 Jul 6;206(7):1495-503
pubmed: 19528259
Cancer Immun. 2013 May 01;13:8
pubmed: 23833565
Biochim Biophys Acta. 2013 Mar;1833(3):680-5
pubmed: 23228566
Blood Adv. 2019 Jul 9;3(13):1970-1980
pubmed: 31266741
Mol Ther. 2020 Jan 8;28(1):52-63
pubmed: 31704085
Blood. 2013 May 2;121(18):3599-608
pubmed: 23487023
J Immunol. 2014 Jan 15;192(2):741-51
pubmed: 24337742
J Biomed Biotechnol. 2011;2011:676198
pubmed: 21541191
Cancer Immunol Immunother. 2018 Sep;67(9):1407-1416
pubmed: 29978334
Clin Cancer Res. 2016 Feb 1;22(3):596-608
pubmed: 26423796
J Immunol. 1997 Aug 15;159(4):1686-94
pubmed: 9257829
J Biol Chem. 2007 May 4;282(18):13167-79
pubmed: 17327231
Scientifica (Cairo). 2014;2014:205796
pubmed: 25054077
Front Cell Infect Microbiol. 2017 Apr 25;7:138
pubmed: 28487846
Biol Blood Marrow Transplant. 2014 Aug;20(8):1252-7
pubmed: 24816582
J Immunol. 1998 Jul 1;161(1):400-8
pubmed: 9647249
Clin Cancer Res. 2020 Jun 1;26(11):2573-2581
pubmed: 32034075
Front Immunol. 2020 May 19;11:868
pubmed: 32508818
J Leukoc Biol. 2012 Sep;92(3):667-72
pubmed: 22623356
PLoS One. 2013 Jun 05;8(6):e64384
pubmed: 23755121
Blood. 2010 Aug 26;116(8):1299-307
pubmed: 20505160
Blood. 2011 Jul 21;118(3):786-94
pubmed: 21628404
Curr Pharm Des. 2009;15(20):2319-35
pubmed: 19601834
MAbs. 2016 Nov/Dec;8(8):1598-1605
pubmed: 27610476
Cancers (Basel). 2019 Jun 03;11(6):
pubmed: 31163679
Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2731-6
pubmed: 10694580
Proc Natl Acad Sci U S A. 1990 Mar;87(6):2244-8
pubmed: 2179952
Hematology Am Soc Hematol Educ Program. 2013;2013:234-46
pubmed: 24319186
Proc Natl Acad Sci U S A. 2011 Apr 5;108(14):5578-83
pubmed: 21415364
Front Immunol. 2019 May 14;10:1068
pubmed: 31139190
Sci Rep. 2017 Dec 8;7(1):17230
pubmed: 29222435
Biochim Biophys Acta Mol Cell Res. 2017 Nov;1864(11 Pt B):2059-2070
pubmed: 28705384
JCI Insight. 2018 Feb 8;3(3):
pubmed: 29415897
J Hematol Oncol. 2021 Jan 6;14(1):7
pubmed: 33407739
J Immunol. 1998 May 15;160(10):5113-21
pubmed: 9590263
Am J Physiol. 1992 Oct;263(4 Pt 2):H1034-44
pubmed: 1384360
J Immunol. 2009 Jan 1;182(1):49-53
pubmed: 19109134
PLoS One. 2015 Mar 27;10(3):e0121788
pubmed: 25816339
J Leukoc Biol. 2019 Jun;105(6):1297-1303
pubmed: 30786043
J Immunol. 2013 Apr 15;190(8):4255-62
pubmed: 23509354
Gynecol Oncol. 2017 Jun;145(3):453-461
pubmed: 28236454
Int J Cancer. 2013 Oct 1;133(7):1557-66
pubmed: 23526433
Cytokine Growth Factor Rev. 2017 Dec;38:10-21
pubmed: 28888485
Cancer Res. 2009 Mar 15;69(6):2531-9
pubmed: 19258505
Immunity. 2003 Nov;19(5):713-24
pubmed: 14614858
Mol Cancer Ther. 2015 Jul;14(7):1637-49
pubmed: 25948294
JCI Insight. 2019 Jun 18;5:
pubmed: 31211693
Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7538-42
pubmed: 1715568
Int J Mol Sci. 2020 Sep 12;21(18):
pubmed: 32932701
Cancer Res. 2014 Jul 1;74(13):3429-40
pubmed: 24780758
Int Arch Allergy Immunol. 1996 Aug;110(4):308-13
pubmed: 8768796
Clin Transl Immunology. 2020 Dec 22;9(12):e1230
pubmed: 33363734
Cancer Res. 2008 Aug 1;68(15):6368-76
pubmed: 18676862